NCT07294859Recruiting

Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy

A Prospective Clinical Study on the Predictive Value of CEUS and Super-resolution Imaging Technology for Renal Function Outcome in Patients After Partial or Radical Nephrectomy

Source: ClinicalTrials.gov · Last updated 19 Dec 2025

Brief summary (registry, in English)

The goal of this prospective cohort study is to evaluate the predictive value of Contrast-Enhanced Ultrasound (CEUS) and Super-Resolution Imaging (SRI) technologies regarding renal function outcomes in patients with renal cell carcinoma (RCC) undergoing partial or radical nephrectomy. The main questions it aims to answer are: Can quantitative parameters of renal microcirculation and microvascular structure derived from CEUS and SRI predict long-term renal function (defined as New Baseline eGFR for radical nephrectomy and Recovery from Ischemia for partial nephrectomy)? Can these imaging parameters accurately predict the occurrence, severity, and early recovery of postoperative acute kidney injury (AKI)? Researchers will monitor the dynamic evolution of renal blood flow and microvascular density by comparing the affected kidney to the contralateral healthy kidney before and after surgery to see if these biomarkers correlate with clinical outcomes. Participants will: Undergo CEUS and SRI examinations before surgery and at specific time points after surgery (e.g., within 7 days) to visualize renal microvasculature. Provide blood and urine samples for standard laboratory tests (such as serum creatinine and Cystatin C) to assess kidney function during hospitalization. Attend follow-up visits at 1, 3, 6, 9, and 12 months post-surgery to monitor long-term renal recovery and complete necessary imaging assessments (CT or Ultrasound).

Status (registry): Recruiting
Study type: Observational
Enrollment: 285 (estimated)
First submitted: 8 Dec 2025
Start date: 1 Sept 2025
Primary completion date: 1 Nov 2027
Lead sponsor: Jinling Hospital, China
Diseases: Kidney cancer
NCT number: NCT07294859

What you commit to

Study type: Observational
Planned participants: 285
From 1 Sept 2025 to the primary completion date, 1 Nov 2027
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Preoperative reliance on renal replacement therapy (such as dialysis, etc.);
The healthy kidney has undergone radiotherapy, ablation or other surgeries.
Accompanied by structural abnormalities of the urinary system or functional abnormalities that cannot be corrected in a short time (such as duplicate kidneys, polycystic kidneys, horseshoe kidneys, isolated kidneys, renal artery stenosis \> 50%, urinary tract obstruction, and previous history of kidney surgery, etc.), long-term indwelling of urinary catheters, etc.
Previous (≤30 days before randomization) or concurrent participation in another clinical study.

Other illness

Have a history of allergy to ultrasound contrast agents;
Have any contraindications for contrast-enhanced ultrasound, such as right-to-left shunt, severe pulmonary hypertension, etc.
There are other diseases that limit life expectancy to less than six months;

Lab values

Patients with solitary kidney or severe contralateral renal insufficiency (eGFR \< 15ml/min/1.73m2);
Patients with hemodynamic instability, including those with persistent hypotension (blood pressure \< 90/60 MMHG), uncontrollable heart failure, active bleeding (such as gastrointestinal and cerebral hemorrhage, etc.), or those with a bleeding tendency and hemoglobin \< 60g/L and/or platelet count \< 50×109/L;

Other

Those who fail to complete the nephrectomy as planned during the operation;
Patients with lymph node metastasis, distant metastasis or venous tumor thrombus;

Who the study is looking for

Fully understood and voluntarily signed the informed Consent Form (ICF);
Age: \> 18 (at the time of signing the informed consent form); Gender is not limited.
Preoperative eGFR \> 45ml/min/1.73m2 (corrected CKD-EPI formula);
After the clinician formulates the treatment plan and communicates with the patient, they decide whether to perform radical nephrectomy or partial nephrectomy.
ECOG score: 0-2 points;
Be willing and able to abide by the visits, treatments, laboratory tests and other procedures of the research plan.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University Coordinator of this site? Confirm its status	Nanjing	China	Recruiting

This page is information, not medical advice. Discuss any trial with your doctor.